NCT06265519 Association of Urine BDNF and NGF With Lower Urinary System Parameters
| NCT ID | NCT06265519 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Marmara University |
| Condition | Benign Prostatic Hyperplasia With Outflow Obstruction |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2024-02-01 |
| Primary Completion | 2026-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2024-02-01 with a primary completion date of 2026-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Histologically, BPH is a benign proliferative process involving both epithelial and stromal elements and is characterised by progressive enlargement of the prostate. Symptom complex including increased frequency of urination, sudden feeling of urge to urinate, nocturia, difficulty in urinating, feeling of incomplete emptying of the bladder, decreased flow rate and intermittent urination are called lower urinary tract symptoms (LUTS). The most important cause of LUTS in men is BPH. Many structural and physiological changes occur in the lower urinary system with bladder outlet obstruction. Detrusor hypertrophy and bladder hyperactivity may occur due to bladder outlet obstruction. Although the density of afferent and efferent nerves in the bladder decreases after urethral obstruction, enlargement of their trunks indicates that changes occur in these nerves. In addition, changes also occur in the neural pathways of the central nervous system following lower urinary tract obstruction. Nerve growth factor (NGF) and brain derived neurotropin factor (BDNF) are trophic proteins that act as retrograde messengers between peripheral effector tissue and the nerves that innervate it. In peripheral tissues, the source of NGF and BDNF is presumed to be the target tissues innervated by nerves. Smooth muscle cells, fibroblasts, astrocytes and other cells synthesise NGF and BDNF in culture medium. Many potential stimuli that increase NGF in the lower urinary system have been identified. These are denervation, inflammation and mechanical tension. This information has led to the idea that autonomic innervation changes in the bladder may be related with changing NGF levels. Altered afferent and adrenergic innervation in the obstructed bladder increases the possibility that NGF plays an important role in this neural growth because this type of nerves are highly sensitive to this neurotrophin. In this study, we investigated NGF ve BDNF levels in urine samples obtained before surgery (Transurethral Prostate Resection, Prostate Enucleation with Holmium Laser and Prostate Enucleation with Thulium Fibre Laser) and after removal of obstruction in patients with bladder outlet obstruction secondary to benign prostatic enlargement using ELISA method, We aimed to determine the role of NGF and BDNF in bladder outlet obstruction and bladder changes secondary to obstruction by comparing with control patients without obstruction.
Eligibility Criteria
Inclusion Criteria: 1. 50-80 years Male 2. Patients with bladder outlet obstruction secondary to benign prostate hyperplasia Exclusion Criteria: 1. Known neurological disease 2. Diabetes 3. Urinary tract infection 4. Previous prostate surgery 5. Spinal Cord Trauma 7-Bladder stone 8-Cerebrovascular disease 9-Chronic Renal Failure 10-Ureteral stenosis
Contact & Investigator
Tufan Tarcan, Prof. Dr.
STUDY DIRECTOR
Marmara University
Frequently Asked Questions
Who can join the NCT06265519 clinical trial?
This trial is open to male participants only, aged 50 Years or older, up to 80 Years, studying Benign Prostatic Hyperplasia With Outflow Obstruction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06265519 currently recruiting?
Yes, NCT06265519 is actively recruiting participants. Contact the research team at kamilcam@hotmail.com for enrollment information.
Where is the NCT06265519 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT06265519 clinical trial?
NCT06265519 is sponsored by Marmara University. The principal investigator is Tufan Tarcan, Prof. Dr. at Marmara University. The trial plans to enroll 70 participants.